Altern Ther Health Med. 2023 Mar;29(2):125-131.
The aim of this study was to observe the effect of astragalus injection on rats with preeclampsia.
A total of 30 pregnant Sprague Dawley (SD) rats were randomly assigned to the model group (MG), the astragalus group (AG) or the control group (CG), with 10 rats in each group. The rat model of preeclampsia was established by subcutaneous injection of 50 mg/(kg∙d) of N-nitro-L-arginine methyl ester (L-NAME), and 0.024 ml/(g∙d) astragalus injection was administered intraperitoneally. The arterial pressure, urinary protein, placental mass, fetal weight, inflammatory factors in peripheral blood of pregnant rats, protein and mRNA levels of nuclear factor- κB (NF-κB), matrix metalloproteinase-9 (MMP-9), nuclear transcription factor 5 (NFAT-5), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and reactive oxygen species (ROS) activity, malondialdehyde (MDA) and nitric oxide (NO) levels in placental tissues were compared in the 3 groups.
After treatment, the arterial pressure and urinary protein levels in pregnant rats in the MG group were significantly higher than in the CG and AG groups (P < .05). The placental mass in the MG group was lower than in the CG and AG groups (P < .05). The messenger RNA (mRNA) and protein levels of sFlt-1, NFAT-5 and NF-κB, as well as ROS activity, MDA, inerleukin (IL)-6, tumor necrosis factor alpha (TNF-α) and interferon gamma (INF-γ) in the AG group were significantly lower than in the MG group, and mRNA and protein expression of MMP-9 and PlGF, as well as the NO level in the AG group, were significantly higher than in the MG (P < .05).
Astragalus injection can effectively inhibit the expression of sFlt-1, NFAT-5, NF-κB and enhance the expression of PlGF and MMP-9 in the placental tissue of rats with preeclampsia, which may be the mechanism of preeclampsia treatment.
本研究旨在观察黄芪注射液对先兆子痫大鼠的作用。
将 30 只妊娠 Sprague Dawley（SD）大鼠随机分为模型组（MG）、黄芪组（AG）和对照组（CG），每组 10 只。通过皮下注射 50mg/（kg·d）N-硝基-L-精氨酸甲酯（L-NAME）建立先兆子痫大鼠模型，并腹腔内注射 0.024ml/（g·d）黄芪注射液。比较 3 组大鼠的动脉压、尿蛋白、胎盘质量、胎儿体重、妊娠大鼠外周血炎症因子、核因子-κB（NF-κB）、基质金属蛋白酶-9（MMP-9）、核转录因子 5（NFAT-5）、胎盘生长因子（PlGF）、可溶性 fms 样酪氨酸激酶-1（sFlt-1）、胎盘组织中活性氧（ROS）活性、丙二醛（MDA）和一氧化氮（NO）水平。
治疗后，MG 组妊娠大鼠的动脉压和尿蛋白水平明显高于 CG 和 AG 组（P＜0.05）。MG 组的胎盘质量低于 CG 和 AG 组（P＜0.05）。AG 组的 sFlt-1、NFAT-5 和 NF-κB 的 mRNA 和蛋白水平以及 ROS 活性、MDA、白细胞介素（IL）-6、肿瘤坏死因子α（TNF-α）和干扰素γ（INF-γ）均明显低于 MG 组，AG 组的 MMP-9 和 PlGF 的 mRNA 和蛋白表达以及 NO 水平均明显高于 MG 组（P＜0.05）。
黄芪注射液能有效抑制先兆子痫大鼠胎盘组织中 sFlt-1、NFAT-5、NF-κB 的表达，增强 PlGF 和 MMP-9 的表达，这可能是其治疗先兆子痫的机制。
